Cargando…

Rapamycin-Loaded Polymeric Nanoparticles as an Advanced Formulation for Macrophage Targeting in Atherosclerosis

Recently, rapamycin (Rapa) represents a potential drug treatment to induce regression of atherosclerotic plaques; however, its use requires site-specific accumulation in the vessels involved in the formation of the plaques to avoid the systemic effects resulting from its indiscriminate biodistributi...

Descripción completa

Detalles Bibliográficos
Autores principales: Craparo, Emanuela Fabiola, Cabibbo, Marta, Conigliaro, Alice, Barreca, Maria Magdalena, Musumeci, Teresa, Giammona, Gaetano, Cavallaro, Gennara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067637/
https://www.ncbi.nlm.nih.gov/pubmed/33916918
http://dx.doi.org/10.3390/pharmaceutics13040503
_version_ 1783682850449522688
author Craparo, Emanuela Fabiola
Cabibbo, Marta
Conigliaro, Alice
Barreca, Maria Magdalena
Musumeci, Teresa
Giammona, Gaetano
Cavallaro, Gennara
author_facet Craparo, Emanuela Fabiola
Cabibbo, Marta
Conigliaro, Alice
Barreca, Maria Magdalena
Musumeci, Teresa
Giammona, Gaetano
Cavallaro, Gennara
author_sort Craparo, Emanuela Fabiola
collection PubMed
description Recently, rapamycin (Rapa) represents a potential drug treatment to induce regression of atherosclerotic plaques; however, its use requires site-specific accumulation in the vessels involved in the formation of the plaques to avoid the systemic effects resulting from its indiscriminate biodistribution. In this work, a stable pharmaceutical formulation for Rapa was realized as a dried powder to be dispersed extemporaneously before administration. The latter was constituted by mannitol (Man) as an excipient and a Rapa-loaded polymeric nanoparticle carrier. These nanoparticles were obtained by nanoprecipitation and using as a starting polymeric material a polycaprolactone (PCL)/α,β-poly(N-2-hydroxyethyl)-dl-aspartamide (PHEA) graft copolymer. To obtain nanoparticles targeted to macrophages, an oxidized phospholipid with a high affinity for the CD36 receptor of macrophages, the 1-(palmitoyl)-2-(5-keto-6-octene-dioyl) phosphatidylcholine (KOdia-PC), was added to the starting organic phase. The chemical–physical and technological characterization of the obtained nanoparticles demonstrated that: both the drug loading (DL%) and the entrapment efficiency (EE%) entrapped drug are high; the entrapped drug is in the amorphous state, protected from degradation and slowly released from the polymeric matrix; and the KOdia-PC is on the nanoparticle surface (KP-Nano). The biological characterization demonstrated that both systems are quickly internalized by macrophages while maintaining the activity of the drug. In vitro studies demonstrated that the effect of KP-Nano Rapa-loaded, in reducing the amount of the Phospo-Ser757-ULK1 protein through the inhibition of the mammalian target of rapamycin (mTOR), is comparable to that of the free drug.
format Online
Article
Text
id pubmed-8067637
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80676372021-04-25 Rapamycin-Loaded Polymeric Nanoparticles as an Advanced Formulation for Macrophage Targeting in Atherosclerosis Craparo, Emanuela Fabiola Cabibbo, Marta Conigliaro, Alice Barreca, Maria Magdalena Musumeci, Teresa Giammona, Gaetano Cavallaro, Gennara Pharmaceutics Article Recently, rapamycin (Rapa) represents a potential drug treatment to induce regression of atherosclerotic plaques; however, its use requires site-specific accumulation in the vessels involved in the formation of the plaques to avoid the systemic effects resulting from its indiscriminate biodistribution. In this work, a stable pharmaceutical formulation for Rapa was realized as a dried powder to be dispersed extemporaneously before administration. The latter was constituted by mannitol (Man) as an excipient and a Rapa-loaded polymeric nanoparticle carrier. These nanoparticles were obtained by nanoprecipitation and using as a starting polymeric material a polycaprolactone (PCL)/α,β-poly(N-2-hydroxyethyl)-dl-aspartamide (PHEA) graft copolymer. To obtain nanoparticles targeted to macrophages, an oxidized phospholipid with a high affinity for the CD36 receptor of macrophages, the 1-(palmitoyl)-2-(5-keto-6-octene-dioyl) phosphatidylcholine (KOdia-PC), was added to the starting organic phase. The chemical–physical and technological characterization of the obtained nanoparticles demonstrated that: both the drug loading (DL%) and the entrapment efficiency (EE%) entrapped drug are high; the entrapped drug is in the amorphous state, protected from degradation and slowly released from the polymeric matrix; and the KOdia-PC is on the nanoparticle surface (KP-Nano). The biological characterization demonstrated that both systems are quickly internalized by macrophages while maintaining the activity of the drug. In vitro studies demonstrated that the effect of KP-Nano Rapa-loaded, in reducing the amount of the Phospo-Ser757-ULK1 protein through the inhibition of the mammalian target of rapamycin (mTOR), is comparable to that of the free drug. MDPI 2021-04-07 /pmc/articles/PMC8067637/ /pubmed/33916918 http://dx.doi.org/10.3390/pharmaceutics13040503 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Craparo, Emanuela Fabiola
Cabibbo, Marta
Conigliaro, Alice
Barreca, Maria Magdalena
Musumeci, Teresa
Giammona, Gaetano
Cavallaro, Gennara
Rapamycin-Loaded Polymeric Nanoparticles as an Advanced Formulation for Macrophage Targeting in Atherosclerosis
title Rapamycin-Loaded Polymeric Nanoparticles as an Advanced Formulation for Macrophage Targeting in Atherosclerosis
title_full Rapamycin-Loaded Polymeric Nanoparticles as an Advanced Formulation for Macrophage Targeting in Atherosclerosis
title_fullStr Rapamycin-Loaded Polymeric Nanoparticles as an Advanced Formulation for Macrophage Targeting in Atherosclerosis
title_full_unstemmed Rapamycin-Loaded Polymeric Nanoparticles as an Advanced Formulation for Macrophage Targeting in Atherosclerosis
title_short Rapamycin-Loaded Polymeric Nanoparticles as an Advanced Formulation for Macrophage Targeting in Atherosclerosis
title_sort rapamycin-loaded polymeric nanoparticles as an advanced formulation for macrophage targeting in atherosclerosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067637/
https://www.ncbi.nlm.nih.gov/pubmed/33916918
http://dx.doi.org/10.3390/pharmaceutics13040503
work_keys_str_mv AT craparoemanuelafabiola rapamycinloadedpolymericnanoparticlesasanadvancedformulationformacrophagetargetinginatherosclerosis
AT cabibbomarta rapamycinloadedpolymericnanoparticlesasanadvancedformulationformacrophagetargetinginatherosclerosis
AT conigliaroalice rapamycinloadedpolymericnanoparticlesasanadvancedformulationformacrophagetargetinginatherosclerosis
AT barrecamariamagdalena rapamycinloadedpolymericnanoparticlesasanadvancedformulationformacrophagetargetinginatherosclerosis
AT musumeciteresa rapamycinloadedpolymericnanoparticlesasanadvancedformulationformacrophagetargetinginatherosclerosis
AT giammonagaetano rapamycinloadedpolymericnanoparticlesasanadvancedformulationformacrophagetargetinginatherosclerosis
AT cavallarogennara rapamycinloadedpolymericnanoparticlesasanadvancedformulationformacrophagetargetinginatherosclerosis